Sibutramine: current status as an anti-obesity drug and its future perspectives

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.9, Iss.12, 2008-08, pp. : 2161-2173

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Orlistat: its current status as an anti-obesity drug

By Ballinger A. Peikin S.R.

European Journal of Pharmacology, Vol. 440, Iss. 2, 2002-04 ,pp. : 109-117

Elsevier

Access to resources Recommend Favorite

The discovery and status of sibutramine as an anti-obesity drug

By Luque C.A. Rey J.A.

European Journal of Pharmacology, Vol. 440, Iss. 2, 2002-04 ,pp. : 119-128

Elsevier

Access to resources Recommend Favorite

The Current Status and Future Perspectives of Studies of Cannabinoid Receptor 1 Antagonists as Anti-Obesity Agents

Current Topics in Medicinal Chemistry, Vol. 9, Iss. 6, 2009-04 ,pp. : 482-503

Bentham Science Publishers

Access to resources Recommend Favorite

Safety Assessment of an Anti-Obesity Drug (Sibutramine): A Retrospective Cohort Study

By Tyczynski Jerzy E.

Drug Safety, Vol. 35, Iss. 8, 2012-08 ,pp. : 629-644

Adis International

Access to resources Recommend Favorite

Neuropeptide Y receptors as targets for anti-obesity drug development: perspective and current status

By Parker E. Van Heek M. Stamford A.

European Journal of Pharmacology, Vol. 440, Iss. 2, 2002-04 ,pp. : 173-187

Elsevier

Access to resources Recommend Favorite